ARCON: A novel biology-based approach in radiotherapy

Lancet Oncology

Volumn 3, Issue 12, 2002, Pages 728-737

  Kaanders, Johannes H A M ^a   Bussink, Johan ^a   Van der Kogel, Albert J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; BIOCHEMICAL MARKER; CARBOGEN; DOMPERIDONE; NICOTINAMIDE;

ACCELERATED RADIOTHERAPY WITH CARBOGEN AND NICOTINAMIDE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BLADDER DISEASE; BONE NECROSIS; BREAST CARCINOMA; CANCER CONTROL; CANCER RADIOTHERAPY; CELL CLONING; CELL HYPOXIA; CELL POPULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; ENTEROPATHY; EXPERIMENTAL NEOPLASM; FEASIBILITY STUDY; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER TOXICITY; MOUSE; NAUSEA AND VOMITING; NEUROTOXICITY; NONHUMAN; PERFUSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; REVIEW; SKIN MANIFESTATION; SPINAL CORD DISEASE; TUMOR CELL;

EID: 0036898268     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00929-4     Document Type: Review

References (75)

1. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131-46.
2. Rojas A, Hirst VK, Calvert AS, Johns H. Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy. Int J Radiat Oncol Biol Phys 1996; 34: 357-65.
3. Petersen C, Zips D, Krause M, et al. Repopulation of FaDu human squamous cell carcinoma during fractionated. Int J Radiat Oncol Biol Phys 2001; 51: 483-93.
4. Kaanders JHAM, van der Kogel AJ, Ang KK. Altered fractionation: limited by mucosal reactions? Radiother Oncol 1999; 50: 247-60.
5. Garden AS. Altered fractionation for head and neck cancer. Oncology (Huntingt) 2001; 10: 1326-32, 1334, 1339-41.
6. Saunders MI, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet 1997; 350: 161-65.
7. Mottram JC. A factor of importance in the radiosensitivity of tumours. Br J Radiol 1936; 9: 606-14.
8. Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48.
9. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76.
10. Vaupel P. Tumor blood flow. In: Molls M, Vaupel P (Eds). Blood perfusion and microenvironment of human tumors. Berlin: Springer-Verlag 1998; 41-45.
11. Höckel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-15.
12. 2)n the in vivo radiation response of a murine sarcoma. Int J Radiat Oncol Biol Phys 1977; 2: 903-11.
13. Thews O, Kelleher DK, Vaupel P. Dynamics of tumor oxygenation and red blood cell flux in response to inspiratory hyperoxia combined with different levels of inspiratory hypercapnia. Radiother Oncol 2002; 62: 77-85.
14. Ljungkvist ASE, Bussink J, Rijken PFJW, et al. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 2000; 48: 1529-38.
15. Bussink J, Kaanders JHAM, Strik AM, van der Kogel AJ. Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescence-based fiber optic probes. Radiother Oncol 2000; 57: 21-30.
16. 2, microcirculatory function and radiosensitivity. Int J Radiat Oncol Biol Phys 1998; 40: 943-51.
17. Rijpkema M, Kaanders JHAM, Joosten FBM, et al. Effects of carbogen breathing on oxygenation and vascularity of head and neck tumors as measured by MRI. Int J Radiat Oncol Biol Phys 2002; 53: 1185-1191.
18. Powell MEB, Collingridge DR, Saunders MI, et al. Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol 1999; 50: 167-71.
19. Aquino-Parsons C, Green A, Minchinton AI. Oxygen tension in primary gynaecological tumours: the influence of carbon dioxide concentration. Radiother Oncol 2000; 57: 45-51.
20. Brizel DM, Lin S, Johnson JL, et al. The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation. Br J Cancer 1995; 72: 1120-24.
21. Robinson SP, Rodrigues LM, Ojugo AS, et al. The response to carbogen breathing in experimental tumour models monitored by gradient-recalled echo magnetic resonance imaging. Br J Cancer 1997; 75: 1000-06.
22. Kruuv JA, Inch WR, McCredie JA. Blood flow and oxygenation of tumors in mice: I, effects of breathing gases containing carbon dioxide at atmospheric pressure. Cancer 1967; 20: 51-59.
23. Kaanders JHAM, Pop LAM, Marres HAM, et al. Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity. Radiother Oncol 1995; 37: 190-98.
24. Kaanders JHAM, Pop LAM, Marres HAM, et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol 1998; 48: 115-22.
25. Hoskin PJ, Abdelath O, Phillips H, et al. Inspired and expired gas concentrations in man during carbogen breathing. Radiother Oncol 1999; 51: 175-77.
26. Kaanders JHAM, Pop LAM, Marres HAM, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Oncol Biol Phys 2002; 52: 769-78.
27. Horsman MR, Chaplin DJ, Brown JM. Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res 1989; 118: 139-50.
28. Chaplin DJ, Horsman MR, Trotter MJ. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst 1990; 82: 672-76.
29. Rojas A, Denekamp J, Johns H, et al. Nicotinamide as a repair inhibitor in vivo: studies using single and fractionated X-ray doses in mouse skin and kidneys. Radiat Res 1996; 145: 419-31.
30. Brown DM, Evans JW, Brown JM. The influence of inhibitors of poly (ADP-ribose) polymerase on X-ray-induced potentially lethal damage repair. Br J Cancer Suppl 1984; 6: 27-31.
31. Kelleher DK, Vaupel PW. Nicotinamide exerts different acute effects on microcirculatory function and tissue oxygenation in rat tumors. Int J Radiat Oncol Biol Phys 1993; 26: 95-102.
32. Honess DJ, Bleehen NM, Effects of the radiosensitising agent nicotinamide on relative tissue perfusion and kidney function in C3H mice. Radiother Oncol 1993; 27: 140-48.
33. Kelleher DK, Vaupel PW. Possible mechanisms involved in tumor radiosensitization following nicotinamide administration. Radiother Oncol 1994; 32: 47-53.
34. Rojas A, Hodgkiss RJ, Stratford MR, et al. Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. Br J Cancer 1993; 68: 1115-21.
35. Horsman MR, Hoyer M, Honess DJ, et al. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol 1993; 27: 131-39.
36. Stratford MR, Dennis MF, Hoskin PJ, et al. Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. Acta Oncol 1996; 35: 213-19.
37. Kaanders JHAM, Stratford MRL, Liefers J, et al. Administration of nicotinamide during a five to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance. Radiother Oncol 43: 67-73, 1997.
38. Hoskin PJ, Stratford MR, Saunders MI, et al. Administration of nicotinamide during CHART: pharmacokinetics, dose escalation, and clinical toxicity. Int J Radiat Oncol Biol Phys 1995; 32: 1111-19.
39. Bussink J, Stratford MRL, van der Kogel AJ, et al. Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. Radiother Oncol 2002; 63: 285-91.
40. Goodchild K, Hill S, Hoskin PJ, et al. The effect of carbogen and differing dose levels of nicotinamide on human tumour blood flow using laser doppler flowmetry. J Clin Oncol 1999; 18 (Suppl): 443a (Abstr).
41. Ruddock MW, Burns DM, Murphy LE, et al. The effect of nicotinamide on spontaneous and induced activity in smooth and skeletal muscle. Radiother Oncol 2000; 56: 253-57.
42. Dorie MJ, Menke D, Brown JM. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int J Radiat Oncol Biol Phys 1994; 28: 145-50.
43. Simon JM, Lartigau E, Guichard M. Nicotinamide and carbogen: major effect on the radiosensitivity of EMT6 and HRT18 tumours. Radiother Oncol 1993; 28: 203-07.
44. Kjellen E, Joiner MC, Collier JM, et al. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol 1991; 22: 81-91.
45. Horsman MR, Siemann DW, Chaplin DJ, Overgaard J. Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother Oncol 1997; 45: 167-74.
46. Haustermans K, van der Kogel AJ, Vanacker B, van der Schueren E. Influence of combined use of nicotinamide and carbogen on rat spinal cord radiation tolerance. Radiother Oncol 1994; 31: 123-28.
47. Dische S. Hyperbaric oxygen: the Medical Research Council trials and their clinical significance. Br J Radiol 1978; 51: 888-94.
48. Dische S. What have we learnt from hyperbaric oxygen? Radiother Oncol 1991; 20 (Suppl): 71-74.
49. Rubin P, Hanley J, Keys HM, et al. Carbogen breathing during radiation therapy: the Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys 1979; 5: 1963-70.
50. Martin L, Lartigau E, Weeger P, et al. Changes in the oxygenation of head and neck tumors during carbogen breathing. Radiother Oncol 1993; 27: 123-30.
51. Dische S, Rojas A, Rugg T, et al. Carbogen breathing-a system for use in man. Br J Radiol 1992; 65: 87-90.
52. Pigott K, Dische S, Saunders MI. Short communication: the addition of carbogen and nicotinamide to a palliative fractionation schedule for locally advanced breast cancer. Br J Radiol 1995; 68: 215-18.
53. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and locoregional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000; 57: 39-43.
54. Wijffels KIEM, Kaanders JHAM, Rijken PFJW, et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer 2000; 83: 674-83.
55. Saunders MI, Hoskin PJ, Pigott K, et al. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study. Radiother Oncol 1997; 45: 159-66.
56. Zackrisson B, Franzen L, Henriksson R, et al. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). Acta Oncol 1994; 33: 377-81.
57. Bernier J, Denekamp J, Rojas A, et al. ARCON; accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiother Oncol 2000; 55: 111-19.
58. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 1985; 11: 1699-707.
59. Shibuya M, Ito S, Davis RL, et al. A new method for analyzing the cell kinetics of human brain tumors by double labeling with bromodeoxyuridine in situ and with iododeoxyuridine in vitro. Cancer 1993; 71: 3109-13.
60. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994; 29: 427-31.
61. Bernsen HJ, Rijken PF, Peters H, et al. Hypoxia in a human intracerebral glioma model. J Neurosurg 2000; 93: 449-54.
62. van der Maazen RWM, Thijssen HOM, Kaanders JHAM, et al. Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. Radiother Oncol 1995; 35: 118-22.
63. Pickles T, Graham P, Syndikus I, et al. Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma. Radiother Oncol 1996; 40: 245-47.
64. Fatigante L, Ducci F, Cartei F, et al. Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment. Int J Radiat Oncol Biol Phys 1997; 37: 499-504.
65. Miralbell R, Mornex F, Greiner R, et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol 1999; 17: 3143-49.
66. Bernier J, Denekamp J, Rojas A, et al. ARCON:accelerated radiotherapy with carbogen and nicotinamide in non-small-cell lung cancer: a phase I/II study by the EORTC. Radiother Oncol 1999; 52: 149-56.
67. Hoskin PJ, Saunders MI, Dische S. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer 1999; 86: 1322-28.
68. Maciejewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991; 21: 163-70.
69. De Neve W, Lybeert ML, Goor C, et al. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 1995; 36: 183-88.
70. Wykoff CC, Beasley NJP, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075-83.
71. Jones A, Fujiyama C, Blanche C, et al. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin Cancer Res 2001; 7: 1263-72.
72. Overgaard J, Horsman MR, Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996; 6: 10-21.
73. Sengeløv L, von der Maase H. Radiotherapy in bladder cancer. Radiother Oncol 1999; 52: 1-14.
74. Begg AC, Haustermans K, Hart AAM, et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol 1999; 50: 13-23.
75. Airley R, Loncaster J, Davidson S, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001; 7: 928-34.